FREEPORT, N.Y., Feb. 2 /PRNewswire/ -- AGI Dermatics today announced new comparative clinical data that indicates a novel patented form of L- ergothioneine (EGT) acts as a more powerful antioxidant than idebenone, scavenging reactive oxygen species 1.4 times faster and reducing hydrogen peroxide (H2O2) twice as fast. The data was presented in the Poster Session at the 65th Annual Meeting of the American Academy of Dermatology in Washington, DC.
"We are very excited that this new patented form of L-ergothioneine exhibited properties of a super-antioxidant in clinical studies," said Dan Yarosh, PhD, President, AGI Dermatics. "Because idebenone has always been regarded as having exceptional antioxidant properties, the research raises the bar for the industry. It also confirms the importance of EGT in future topical applications designed to repair and prevent cellular damage to the skin."
The study compared the abilities of idebenone and EGT to reduce hydrogen peroxide when added directly to cell culture media without cells and also when hydrogen peroxide was generated by UVA340 exposure of normal human dermal fibroblasts (NHDF).
Media containing 1mM hydrogen peroxide was treated with 150uM-L EGT or idebenone for two hours. EGT scavenged hydrogen peroxide directly from the media at approximately 1.4 times the rate of idebenone. Measurement of dihydrohodamine 123 oxidation resulted in a 39% decrease in hydrogen peroxide with treatment of L-ergothioneine while only a 23% reduction was seen with idebenone.
To examine the influence of these two antioxidants on UVA340-induced hydrogen peroxide, NHDF were treated with 10uM EGT or idebenone in phenol red-free media 24 hours before irradiation with 100kJ/m UVA340. Levels of hydrogen peroxide were measured just before irradiation, immediately after and one hour later with dihydrohodamine 123. Results show that idebenone does not reduce hydrogen peroxide in the media immediately after irradiation, but does so an hour after irradiation. In contrast L-ergothioneine significantly reduces hydrogen peroxide immediately after irradiation by 345% and continues the reduction one hour after irradiation by 64%.
"Hydrogen Peroxide is a nonradical active oxygen species that, when induced by UVA340 exposure, releases levels of oxygen which assault and challenge the skin, thereby contributing to the appearance of fine lines and wrinkles," said Dr. Yarosh. "We found EGT outperformed idebenone at all UVA340 doses in the lab tests, confirming its beneficial role in the treatment of photodamaged skin."
AGI Dermatics is the developer of Remergent(R), a doctor-dispensed skincare line based on the science of DNA repair. AGI manufactures Remergent(R) Clarifying Concentrate, a formula designed to treat hyperpigmentation, which contains EGT, which has also been shown to be clinically effective in enhancing skin brightness. EGT is also found in other Remergent products, including Remergent HQ, a 4% hydroquinone skin lightening cream.
AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com.
For press inquiries please contact RPR Marketing Communications at 212-317-1462
Available Topic Expert: For information on the listed expert, click appropriate link. Daniel Yarosh, PhD, President, AGI Dermatics http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=57840
AGI DermaticsCONTACT: RPR Marketing Communications, +1-212-317-1462, for AGI Dermatics
Web site: http://www.agiderm.com//
